RSV outcomes: Maternal vs. infant immunization

Researchers have examined the efficacy of maternal versus infant immunization approaches in the prevention of respiratory syncytial virus-related hospitalization.

In a study published in JAMA, investigators used data from the French National Health Data System to assess outcomes with passive infant immunization with nirsevimab immunization prior to hospital discharge compared with maternal RSV prefusion F protein vaccination between weeks 32 to 36 of gestation among more than 40,000 infants.

The investigators found that the infants who received nirsevimab were less likely to experience RSV-related hospitalization, be admitted to the pediatric ICU and receive ventilator support or oxygen therapy compared with those whose mothers received the RSV prefusion F protein vaccine during pregnancy.

Despite the positive findings, the investigators indicated that further studies are needed to validate the efficacy of nirsevimab immunization.

Read more: JAMA

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.